



Ohio Bioscience Growth Report
Update
August, 2006



Ohio Bioscience Growth Report
Update
August, 2006



1275 Kinnear Rd.
Columbus, OH 43212
614.675.3686
www.omeris.org
bioscience@omeris.org

Introduction by Omeris President & CEO Anthony J. Dennis, PhD

In 2005 Ohio's bioscience industry continued to enjoy significant growth in all phases of the biosciences, from research and development funding to rates of formation of new and emerging companies.

The state continues to accelerate funding—not only of strategic, technology-based initiatives that leverage existing Ohio strengths but also seed, pre-seed and early stage funds to fuel company formation and growth from those initiatives. Key aspects of this aggressive funding include private-sector matching dollars applied to Ohio Third Frontier Project initiatives and the collaboration of academic institutions and the private sector.



Ohio bioscience also added a public company in 2005, as AtriCure successfully launched an IPO last August. And although not included in this report, Cleveland BioLabs recently launched its own IPO. These are clear indications of the quality and potential of emerging companies in our state.

Ohio's major academic research centers are being more aggressive and effective in technology transfer and company formation. And Ohio's corporate bioscience leaders are stepping up in an unprecedented way to participate in both regional and statewide commercial activities at the grass roots.

Last year was an exciting period for bioscience growth in Ohio, and all indications are that 2006 holds much of the same.

A handwritten signature in black ink, appearing to read "Anthony J. Dennis".

Omeris Board of Trustees

John A. Bantle, II, PhD

Vice President, Research
Ohio University

Timothy G. Biro

Managing Partner
Ohio Innovation Fund
Reservoir Venture Partners

Thomas F. Boat, MD

Director
Cincinnati Children's Hospital Medical Center

Mark A. Collar

President, Global Pharmaceuticals
& Personal Health
Procter & Gamble

Mark Coticchia

V.P., Research & Technology Management
Case Western Reserve University

Anthony J. Dennis, PhD

President & CEO
Omeris

Jane Henney, MD

Senior V.P. and Provost for Health Affairs
University of Cincinnati

Mike Hooven, Vice Chair

Chairman & CTO
AtriCure

Charles Immel

Group President, Healthcare Group
STERIS Corporation

Peter G. Kleinhenz

General Partner
CID Equity Partners

Richard D. Rosen, Chairman

Vice President of External Business Relations
Battelle Healthcare

John M. Rice, PhD

Managing Partner
Triathlon Medical Ventures

Fred Sanfilippo, MD, PhD

Senior V.P. & Executive Dean for Health Sciences
CEO, OSU Medical Center
The Ohio State University

David R. Scholl, PhD

President & CEO
Diagnostic Hybrids, Inc.

James A. Scozzie, PhD

Senior Vice President
BioEnterprise Corporation

Donald Wetherhold

Vice President
Cardinal Health

Omeris, founded in 1987 as Edison BioTechnology Center, is a non-profit organization designed to build and accelerate bioscience industry, research, and education in Ohio. As Ohio's bioscience membership and development organization, we are focused on networking the distributed and outstanding bioscience assets of Ohio to promote regional, national, and global best of class competitiveness and growth.

Omeris Staff

President & CEO

Anthony J. Dennis, PhD

Vice President

John F. Lewis, Jr.

Senior Program Director

William C. Tacon, PhD

Director, Corporate Communications

Matt Schutte

Vice President, Finance & Administration

William Poore

Chief Operating Officer

Robert A. Baxter

Executive Assistant

Martie Hexamer

Membership Coordinator

Mollie Hannon

In addition to the Omeris staff, we would like to sincerely acknowledge the research, editing and assistance of the following:

- *Ching-Wen Chen | The Ohio State University | Fisher College of Business, MBA, June 2006*
- *Robin Ng | The Ohio State University | Chemical and Biomolecular Engineering PhD Candidate, June 2007*
- *Catharina Maulbecker, PhD, Vice President Sales, CAS | work done as special consultant to Omeris in 2005*

Table of Contents

- 5 Economic Indicators**
 - Number of Bioscience Organizations
 - Types and Distribution of Bioscience Organizations
 - Organization Launches/Recruitment
 - Economic Impact

- 6 Research Indicators**
 - NIH Funding
 - NSF Funding
 - SBIR/STTR Funding
 - Intellectual Property
 - Clinical Network

- 8 Investment Indicators**
 - Total Bioscience Funding
 - Third Frontier Project

- 9 Concluding Remarks**

- 10 2005 Ohio Bioscience News Highlights**

- 12 Footnotes**

Economic Indicators

Ohio is the 7th largest state with 11.5 million residents. Its Gross State Product (GSP) was \$442 billion in 2005, with an annual growth rate of 4.1 percent.

The biosciences are a diverse and often converging group of industries and activities with a common link—they apply knowledge of the way in which plants, animals, and humans function. This report reflects a bioscience sector that spans different markets and includes entities involved in health-related manufacturing, services, and research activities.


Bioscience, medical technology, and research organizations continue to thrive in Ohio. In 2005, 775 bioscience-related entities were operating in the state, ranging from the very large to the very young.

The dispersion of these organizations across Ohio remains consistent with previous years, as more than half (400) of the bioscience entities are located in northeast Ohio, namely Cleveland, its surrounding suburbs, and Akron. Southwest Ohio is home to 176 bioscience-related entities, followed by central Ohio (134), northwest Ohio (37), and the southeast corner of the state (11). Medical device and equipment companies continue to dominate Ohio's bioscience industry with 400 entities, as more traditional manufacturers take on bio-related activities.

Fifty bioscience companies were either launched in or recruited to Ohio in 2005, compared to 51 in 2004. One notable characteristic of this group is its diversity. From chemotherapeutic drugs (Auburn Pharmaceuticals) and therapeutics for multiple sclerosis (OncoImmune) to DNA analysis (Forensic Bioinformatics) and orthopedic screws (Merlot Orthopedix), Ohio's newest bioscience additions are applying technology and service to a variety of market needs.


Nearly half (24) of the new companies located in northeast Ohio. In southwest Ohio, San Diego-based Amylin Pharmaceuticals selected West Chester for its first production facility for a long-acting release (LAR) formulation of exenatide, a product candidate in development for the treatment of type 2 diabetes. The \$70 million project is expected to create up to 150 jobs during its first three years of operation.

Ohio's Third Frontier Project, a \$1.6 billion initiative that expands high-tech research capabilities and promotes innovation and company formation, spawned several new companies in 2005. Cleveland-based StemRx is a spin-out



Just over half of Ohio's bioscience entities are located in northeast Ohio.

50 bioscience companies either were launched in or recruited to Ohio in 2005.



Medical device companies continue to prosper throughout Ohio.

company from the Center for Stem Cell and Regenerative Medicine. Sinus Rhythm Technologies and Symphony Medical, both based in Minnesota, established an Ohio presence as commercialization partners in the Atrial Fibrillation Innovation Center. Outside the scope of Third Frontier Project collaborations, several international companies also opened locations in Ohio, including Aria Analytics, which is based on Russian technology, and Sun Pharmaceutical Industries from India.

Implan software analysis by the Ohio Department of Development and Dr. C. Maulbecker Consulting revealed the economic impact of bioscience companies in Ohio, not including agribusinesses¹, was in excess of \$1.8 billion in 2004 (based on 37,592 jobs with an average salary of \$47,563). Once the healthcare industry is added, the economic impact dramatically increased to \$52 billion in economic gain from 586,000 Ohio jobs with an average salary of \$88,826.

Research Indicators

Ohio's 161 institutions of higher education—per capita more than any other state—are the foundation to its strength in scientific research. The Ohio State University, Case Western Reserve University, and University of Cincinnati are all ranked among the top research facilities in the nation.

NIH Funding


In 2005, Ohio-based institutions and companies received \$717 million in National Institutes of Health (NIH) funding, nearly 4 percent more than in 2004, which compares favorably with the average national growth rate of 2.5 percent.

Outpacing the U.S. average, Ohio's 2005 NIH awards ranked 2nd in the Midwest and 10th in the nation. Moreover, four institutions, Case Western Reserve University, The Ohio State University, University of Cincinnati, and Cincinnati Children's Hospital Medical Center, are among the nation's top 100 NIH funding recipients.


Among benchmark states, Ohio NIH funding surpasses Michigan (\$564 million) and Indiana (\$219 million), but still lags North Carolina, which was awarded \$1.1 billion in 2005.

NSF Funding

In FY2005, the National Science Foundation's (NSF) Directorate of Biological Sciences awarded \$14.8 million in grants to Ohio-based organizations. Ohio's bioscience-related NSF funding was concentrated in central Ohio, due primarily to the relative size and diverse research strengths of The Ohio State University.



Ohio's NIH funding grew by 4 percent in 2005.



SBIR/STTR Funding

SBIR and STTR funding from the U.S. Small Business Administration is a widely accepted metric and peer reviewed validation of emerging technology heading toward commercialization. Ohio received significantly more than the national average of total SBIR/STTR funding. With \$94 million, Ohio ranks 7th nationally and ahead of its benchmark states. SBIR/STTR funding related to bioscience research and product development in Ohio increased 34 percent, from \$21.7 million in 2004 to \$28.9 million in 2005.

Intellectual Property

From 1963-2005, 119,986 patents were filed by Ohioans or Ohio companies, ranking the state 7th nationally.

This historical data underscores a tradition of innovation in Ohio, which also is home to the National Inventors Hall of Fame in Akron. In fact, all of these bioscience breakthroughs were invented by Ohioans:


- Surfactant protein
- Total hip replacement prosthesis
- Kidney dialysis machine
- Sabin oral polio vaccine
- First antihistamine, Benadryl
- First use of YAG1 laser to remove brain tumor
- First vaccine against the feline leukemia virus
- Heimlich maneuver

In 2005, 2,319 patents were filed in Ohio, of which 307 were classified as bio-affecting inventions. The U.S. Patent and Trademark Office (USPTO) includes the following areas under its bio-affecting inventions classification: drugs; medicators; surgical; surgery; prosthesis; optics; food; and several chemistry categories. According to the USPTO, both numbers represent a 20 percent decrease from 2004, consistent with nationwide trends.


Clinical Network

For the third straight year (2003-2005), Ohio was home to the most top-ranked hospitals in the nation. In *U.S. News & World Report's* 2005 "America's Best Hospitals" list, 16 Ohio hospitals were ranked among the nation's top 176 hospitals in a variety of specialties.

Of the 16 Ohio hospitals, The Cleveland Clinic maintained the highest ranking at fourth overall. In addition, Cleveland Clinic's Heart Center again was named the nation's best cardiac care center—a title it has held for 11 consecutive years. The magazine's survey also ranked 16 Cleveland Clinic specialty care areas among the nation's best, with 11 of those specialties ranked among the top 10.



SBIR/STTR funding related to bioscience R&D in Ohio increased 34 percent, from \$21.7 million in 2004 to \$28.9 million in 2005.



Ohio's reputation for clinical excellence helps explain why it hosts at least 20% of all U.S.-based clinical trials in any given year.

Other Ohio hospitals faring well across the board included University Hospitals of Cleveland, with 14 specialty care areas ranked in the top 50, and The Ohio State University Medical Center, with 12 top 50 specialty areas.

According to *U.S. News & World Report's* 2005 rankings, 2 of America's top 10 pediatric hospitals were in Ohio—Cincinnati Children's Hospital Medical Center and Rainbow Babies & Children's Hospital in Cleveland. Ohio also was home to 6 of the top 50 heart centers, 4 top 50 cancer centers, and 6 top 50 neurology centers.

With a very strong clinical network and medical reputation, Ohio hosted 20 percent of all clinical trials conducted in the U.S. As of June 2006, there were 1,475 actively-recruiting clinical trials being conducted in Ohio, ranking it 6th among all states. A majority of these trials are in either Phase II (39 percent) or Phase III (43 percent), and predominantly focus on cardiovascular (44 percent) or cancer (43 percent).

Investment Indicators

Total Bioscience Funding



Overall, more than \$1.2 billion were invested in 94 companies across Ohio to accelerate Ohio's bioscience growth in 2005, a jump of more than \$200 million since 2004. The sources of funding include venture capital, angel funds, IPOs, SBIR/STTR, state biomedical R&D grants, and NSF and NIH grants. The largest portion of this funding came from NIH (\$717 million), which constitutes 60 percent of total investment.

Ohio's Third Frontier Project was another significant source of funding; \$75.35 million were awarded to 7 various biomedical partnerships in 2005, and corresponding corporate and industry matching funds amounted to \$112.45 million.

Among firms attracting venture capital investment in 2005, Beachwood-based AxioMed Spine received \$18 million and Columbus-based specialty pharmaceutical company Ventaira Pharmaceuticals raised \$13.5 million.

Cincinnati-based AtriCure, a surgical medical device company, went public in 2005, raising \$48.9 million from their initial public offering (IPO).

At least 27 companies received \$1 million or more in venture capital, angel financing, or non-dilutive



Total Bioscience Funding (in millions)		
	2005	2004
VC/Angels	\$97.92	\$90.61
Healthcare Equity	\$100	\$0
Other	\$11.69	\$0.5
IPO	\$48.9	\$0
SBIR/STTR	\$22.26	\$21.66
State TFAF	\$0	\$11.9
State Biomedical Partnerships	\$75.35	\$50.72
Matching Funds for Biomedical Partnerships	\$112.4	\$110.9
NSF Bioscience Grants	\$14.81	\$36.13
NIH Institutional Grants	\$716.97	\$661
Total Bioscience Funding	\$1,200.35	\$983.42

competitive federal or state grants. These numbers do not include corporate R&D investments by existing Ohio companies, such as Battelle, Philips Medical Systems, Ethicon Endo-Surgery, Ross Products, and Procter & Gamble, among others.

Third Frontier Project

Between 2002-2005, \$357.7 million of Ohio's Third Frontier Project funds had been competitively awarded, of which 55 percent supported bioscience-related research and development initiatives, referred to as biomedical partnerships. By the end of 2005, 17 total biomedical partnerships had been formed, 7 of which received funding during 2005.

Concluding Remarks

Our second Ohio Bioscience Growth Report is an update to last year's inaugural report. Objective and fact-based, it is intended to give you a snapshot of "Bio in Ohio" during 2005. Key metrics associated with bioscience industry vitality continue to improve, and we believe that the 2006 Ohio Bioscience Growth Report will reveal similar momentum.

For additional information regarding bioscience business and research in Ohio, visit www.omeris.org or call Omeris at 614.675.3686.

2005 Third Frontier Biomedical Partnerships

Funded Projects	Participants	Award Amounts (in millions)	Corporate / Matching Amounts (in millions)
Atrial Fibrillation Innovation Center	Cleveland Clinic, AtriCure, Biocontrol, Boston Scientific, Case Western Reserve University, Cyberonics, Hansen Medical, Philips Medical, St. Jude Medical, SRTI, Symphony Medical, University of Cincinnati, CardioNet and Sinus Rhythm Technologies	\$23	\$47.2
Commercialization Platform of Immunotherapeutics for Cancer and Multiple Sclerosis	The Ohio State University, Oncolmmune, The Battelle Memorial Institute, The Johns Hopkins Medical Center, Cleveland Clinic, Cincinnati Children's Hospital and Cardinal Health	\$4.25	\$4.25
Targeted Nanoparticles for Imaging and Therapeutics	Case Western Reserve University, iMEDD, Copernicus Therapeutics, Ricerca Biosciences and Cleveland NanoCrystals	\$4	\$4
Age-Related Macular Degeneration - Initiative for Prevention & Cure	Cleveland Clinic, Case Western Reserve University and Wright State University	\$6	\$6
Clinical Tissue Engineering Center	Cleveland Clinic, Case Western Reserve University, University Hospitals of Cleveland, Ohio Supercomputer Center, NASA Glenn Research Center, Matrix Biology Institute, Boston University, Massachusetts Institute of Technology, University of Bern, Rice University, University of Utah, University of California, University of Toronto, Zimmer, Becton Dickinson, DePuy, Icoria, Stryker, Wright Medical Group, Invacare, Wyeth Research/Genetics Institute, Johns Hopkins University and University of Washington	\$4	\$4
Ohio BioProducts Innovation Center	The Ohio State University, Albemarle Corporation, Archer Daniels Midland Company, Cargill, Cooperative Business Council, Delphi Packard Electric Systems, National Renewable Energy Laboratory, Ohio Polymer Strategy Council, Ohio Soybean Council, Pacific Northwest National Laboratory, The Scotts Company, and U.S. Department of Agriculture – ARS	\$11.6	\$6
Center for Multifunctional Polymer Nanomaterial and Devices	The Ohio State University, Ohio Polymer, Avery Dennison, Procter & Gamble, Omeris +50 others	\$22.5	\$41

2005 Ohio Bioscience News Highlights

Imalux gets FDA approval and closes funding round

January 4 and January 6, 2005 | Crain's Cleveland Business

Imalux, a medical device company in Cleveland, received clearance from the FDA to begin selling their Niris Imaging System, and closed its \$4.8 million series B financing round.

P&G partners with Taiwan firm to develop drug

January 7, 2005 | Cincinnati Business Courier

P&G has formed an alliance with Taiwanese drug firm TaiGen Biotechnology to handle Phase I and Phase II development of a Procter-invented nonfluorinated quinolone antibiotic.

Children's (Cincinnati) licenses skin technology

January 19, 2005 | Cincinnati Business Courier

Cincinnati Children's Hospital Medical Center signed a licensing deal that gives Girindus AG access to the hospital's portfolio of more than 30 skin-lightening patents. The patents were first gained in 2002 through a donation by P&G.

Ross' formula for success

April 8, 2005 | Columbus Business First

Gary E. McCullough, new president of Ross Products, a division of Abbott Laboratories, is pushing innovation. In April 2005 Ross announced the launch of nutritional shakes and snacks for expectant mothers as a signal of things to come from the company best known for Ensure and Similac.

Gebauer branching out to make outside (medical) products

February 2, 2005 | Cleveland Plain Dealer

Gebauer, a 100 year old maker of topical anesthetics, is creating a business unit with the dual aim of attracting medical device manufacturing work to Cleveland and helping local research institutions turn their inventions into products.

What it costs to operate a biotech facility

February 15, 2005 | Genetic Engineering News

More bang for biotech buck in Ohio

March 24, 2005 | Cleveland Plain Dealer

According to Genetic Engineering News, the annual cost of operating a biotech facility in Columbus (\$9.17 million) is 19 percent less than in San Jose (\$11.29 million) or San Francisco (\$11.22 million), both considered traditional biotech centers. On the East Coast, Boston's biotech operating costs total \$10.62 million, \$1.45 million and \$960,000 more than Columbus and Cleveland, respectively.

Nanotech's Heartland Lift

February 14, 2005 | BusinessWeek online

Cleveland's Five Star Technologies is proving the "Rust Belt" can become part of the "next big thing." This nanotechnology company, based on Ukrainian technology, raised \$4.5 million from venture capitalists.

Investors funnel \$18 million to AxioMed

February 21, 2005 | Crain's Cleveland Business

Investors poured \$18 million into AxioMed Spine Corp. of Beachwood, thus giving the maker of artificial spinal discs the cash infusion needed to start testing their spinal implants on humans.

Investments in bioscience balloon

March 7, 2005 | Crain's Cleveland Business

Northeast Ohio saw a near doubling of venture capital investments in its bioscience companies in 2004 compared to 2003.

Cardinal receives genetic-engineering patent

April 4, 2005 | Columbus Business First

Cardinal Health said it's been granted a U.S. patent on a method to create medicinal compounds using genetic engineering. The method, known as GPEx, is able to clone mammal cells on a large scale.

Ventaira secures \$13.5 million investment

Wednesday, April 6, 2005 | Columbus Dispatch

Ventaira Pharmaceuticals, a Battelle spin-off, landed \$13.5 million worth of venture capital to continue its development of an inhaler for asthmatics. The Columbus company completed a Phase I clinical trial for its Mystic inhalation system, which it hopes will be ready for sale in 2007 or 2008.

Ethicon pioneers tubes for less-invasive surgery

April 25, 2005 | Cincinnati Enquirer

Ethicon Endo-Surgery, a division of J&J, continues to develop instruments for minimally invasive surgery or laparoscopic surgery that result in faster recovery, less pain and a lower risk of surgical complications.

NIH awards funding to biotech firm for heart disease, stem cell research

April 26, 2005 | Medical News Today

Arteriocyte, the first spin-out company from the Case Western Reserve University-based Center for Stem Cell and Regenerative Medicine, has received its first installment of a combined Phase I/II "fast track" STTR grant from the NIH.

Roxane equips plant to handle new drug

May 2, 2005 | Columbus Business First

Demand for the once-a-day drug Spiriva and its associated HandiHaler is expected to increase and has required Roxane and its parent Boehringer Ingelheim to seek approval of the FDA for their expanded facility.

Ganeden has healthy outlook

June 4, 2005 | Cleveland Plain Dealer

Ganeden Biotech, a company that makes over-the-counter treatments for common miseries such as foot fungus and intestinal gas, has been busy boosting product line, workforce and sales. Ganeden currently sells into more than 30,000 pharmaceutical locations nationwide.

Theken buys New Jersey medical device company

July 1, 2005 | Crain's Cleveland Business

Akron's Theken Spine has acquired NJ-based Therics. Therics' more than 50 patents for 3-D printing technology will be integrated into Theken's two medical device companies and allow them to branch into the biodegradable implants market.

Big grants are given in health program to aid poor

June 28, 2005 | Wall Street Journal

The Bill and Melinda Gates Foundation awarded \$7.5 million to Ohio State University's Dr. Richard Sayre to genetically engineer cassava that is high in vitamins and low in cyanide. Dr. Sayre has worked for 16 years to genetically engineer cassava, a bitter staple root with few nutrients and cyanide residues that can kill or inflict nerve damage on the 250-600 million people who subsist on it.

AtriCure IPO raises \$48 million

August 6, 2005 | Cincinnati Enquirer

After setting its IPO price at \$12 a share, the West Chester-based maker of cardiac surgical devices saw investors open bidding at \$12.10 and drive the stock to \$15.45 before it settled at \$14.08, up \$2.08. Nearly 3.1 million shares traded hands.

Survey: Medical devices a key Midwest investment magnet

September 14, 2005 | Medical Device Daily

Bioenterprise's founding and technology partners, Cleveland Clinic, University Hospitals, Case Western Reserve University, Summa Health, NASA Glenn Research, Cleveland State University, Omeris and Nortech have been involved in recruiting and accelerating more than 30 companies over the past year.

Military base changes official (Ohio to gain AFRL bio jobs)

November 8, 2005 | Dayton Business Journal

The closure of Brooks City Base in San Antonio is expected to help Wright Patterson Air Force Base in Dayton become the U.S. Department of Defense's main location for aerospace medicine and human effectiveness (pilot performance) research.

Cleveland Clinic Innovation Summit 2005

December 1, 2005 | Medical Design Magazine

For the third consecutive year, the Cleveland Clinic hosted its Medical Innovations Summit, an unprecedented, international gathering of 700+ decision makers from throughout the health care industry. The October event placed particular emphasis on orthopedic innovations.

NE Ohio investors chase Israeli ideas in bioscience

December 13, 2005 | Cleveland Plain Dealer

With one of the nation's largest Jewish populations, Northeast Ohio has attracted numerous Israeli companies in recent years and is going for more.

Amylin buys Ohio building for \$9 million

December 29, 2005 | BusinessWeek online

San Diego-based Amylin Pharmaceuticals acquires facility in West Chester, Ohio, to manufacture a long-acting release formulation of exenatide, a treatment in development for Type-2 diabetes. The 150,000 square-foot building on 26 acres will create 50-200 jobs over the next 3 years.

Footnotes

¹ (page 6) The national Biotechnology Industry Organization (BIO) recognizes only a portion of agribusiness in its bioscience definition, but Ohio's bioscience community continues to integrate more and more ideas with traditional agricultural opportunities. The 2004 Conway agribusiness report ranks Ohio fourth with \$56 billion in value adding food processing production behind California, Texas, and Illinois. Highlights of Ohio's food processing strengths include:

- the Campbell's soup factory in Napoleon is the world's largest
- more ketchup flows from the Heinz plant in Fremont than anywhere else in the world
- Pillsbury turns out 1.8 billion pizza's a year at the world's largest pizza plant
- Dannon operates the world's largest yogurt plant in Minster
- Cargill's plant in Dayton is the USA's largest fructose-making facility
- more Swiss Cheese is produced in Ohio than Wisconsin
- Toledo is home to the Center for Innovative Food Technology
- and the 7,100 acre Ohio Agricultural Research & Development Center is based in Wooster.

Omeris would like to thank our 230 organizational and individual members, especially our Founding Members listed below:

Battelle

Case Western Reserve University

Cincinnati Children's Hospital Medical Center

Ohio University

Procter & Gamble Pharmaceuticals, Inc.

The Cleveland Clinic Foundation

The Ohio State University

University Hospitals Health System

University of Cincinnati

Ohio Bioscience Growth Report

Update

August, 2006



1275 Kinnear Rd.
Columbus, OH 43212
614.675.3686
www.omeris.org
bioscience@omeris.org